Which stock wins in a match-up between these two biotechs?
Which stock wins in a face-off between an investment spin-off of a leading Canadian cannabis producer and the top U.S. cannabis-focused REIT?
Which stock wins in a match-up between a top Canadian cannabis producer and a leading U.S. cannabis operator?
Less hype, more sanity with these two fast-growing stocks.
They're pioneers. They're innovators. And they should continue to be huge winners for investors with long-term perspectives.
There's no such thing as a no-risk stock. But these three stocks should be much less risky than most.
Which stock wins in a battle between these two big pharma companies?
Here's a hint: The outlook for legalization looks quite sunny.
Which stock wins in a one-on-one matchup between these two leading Canadian cannabis producers?
Rumors that Amgen plans to buy Alexion might not become reality. But a deal would make a lot of sense.
To buy or not to buy? That's the question for GW Pharmaceuticals. And here's the answer.
Hint: Most are years away from delivering consistent profits. But there's one notable exception.
The U.S. cannabis operator saw sales skyrocket. But its spending soared, too.
Is a plunge of 85% or more really in store for one of the biggest Canadian cannabis producers?
The biotech is reeling following the thumbs-down for its experimental DMD drug golodirsen.
The medical device giant beat Wall Street expectations and increased its full-year earnings guidance.
Investors are cheering the drugmaker's settlement in principle of two lawsuits related to its opioid drugs.
Some stocks you merely buy. Others are at the core of your portfolio. These three belong in the latter category.
The charts for these three stocks show the kinds of curves that investors should really like -- trending upward.
The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira.